Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kyzatrex in Menopausal Women with HSDD
NCT06082817Phase 2Not yet recruiting
- Sponsor
- San Diego Sexual Medicine
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vilobelimab in hypoactive sexual desire disorder (HSDD), sponsored by San Diego Sexual Medicine. Primary endpoints: Serum Total Testosterone Concentration at 56 days and Incidence of Adverse Events at 84 days. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
vilobelimab
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT06082817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06082817.